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ABSTRACT 
Background/Aim: The aim of this study was to regenerate transplanted hepatocytes selectively 
in a recipient using retrorsine and recombinant human hepatocyte growth factor (rhHGF). 
Methodology: Nagase analbuminemic rats (NARs) received pretreatment with retrosine and 
were divided into three experimental groups. Group1: Hepatocyte transplantation (HcTx) + 
50μg/kg/day rhHGF. Group2: HcTx + 250μg/kg/day rhHGF. Group3: HcTx + normal saline. 
The serum levels of albumin and the albumin-positive hepatocytes in the liver were investigated. 
The rat endogenous HGF of the rats given only retrorsine was measured. 
Result: The serum albumin levels of Group1 were higher than those of Group2, while there was 
no significant difference between Group2 and Group3. Histological examination of Group1 and 
3 showed the presence of a large number of albumin-positive hepatocytes, which frequently 
consisted of large clusters and occupied 53.90±2.31% and 31.25±5.36% of host liver, 
respectively. The liver sections of Group2 showed numerous albumin-positive hepatocytes, 
which were not seen as clusters. The rat endogenous HGF concentration was extremely high. 
Conclusion: Low-dose rhHGF enhances the effect of HcTx under the suppressive state of 
proliferation of host hepatocytes. Because of the high endogenous HGF, the administration of a 
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high concentration of rhHGF suppressed the regenerative activity of the transplanted 
hepatocytes.
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INTRODUCTION 
    Although the therapy for hepatic metabolic deficient disease still remains orthotopic liver 
transplantation (OLT), the donor organ shortage has been problematic. Hepatocyte 
transplantation (HcTx) has been proposed as an alternative therapy to OLT, but it is difficult to 
regenerate transplanted hepatocytes and to achieve the long term correction of a liver-related 
metabolic defect (1-3). Therefore, partial hepatectomy and portal branch ligation have been 
added as a growth stimulus for transplanted hepatocytes (4-8). However, these invasive methods 
are not suitable in a clinical setting for patients with congenital hepatic metabolic deficiency 
disease. 
   Human hepatocyte growth factor (HGF) was isolated and purified from the plasma of 
patients with fuluminant hepatic failure and was found to stimulate DNA synthesis even in adult 
rat hepatocytes (9, 10). A recombinant form of human hepatocyte growth factor (rhHGF) has 
also been developed and is as effective as the native HGF in terms of proliferative activities in 
rat and human hepatocytes (11). Furthermore, the cytoprotective effect of HGF through the 
immunoregulation action and antiapoptosis action have also been reported (12-15). 
    Recently, nearly total liver replacement by transplanted normal hepatocytes was reported 
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in rats treated with retrorsine (16-18). Retrorsine is a naturally occurring pyrrolizidine alkaloid 
that is taken up selectively by the liver and metabolized to bioactive compounds that alkylate 
DNA, which causes a long-lasting block of hepatocyte cell division (19-23). To selectively 
enhance the proliferation of transplanted hepatocytes, combined therapy with HGF and 
retrorsine seems to be an attractive strategy, although it has never been tested in vivo. 




Animals. All rats used were purchased from Japan SLC Inc.(Shizuoka, Japan) and were 
maintained at the Animal Center at Nagasaki University School of Medicine. Male Nagase 
analbuminemic rats (NARs) were used as the recipients, while male Sprague-Dawley (SD) rats 
were used as the hepatocyte donors. All animals were maintained in a climate-controlled (24℃) 
room with a 12-hour light-dark cycle and were provided tap water and standard laboratory chow 
ad libitum. All procedures were done in accordance with the guidelines of the University of 
Nagasaki Research Animal Resources.  
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Chemicals. Recombinant human hepatocyte growth factor (rhHGF) was manufactured and 
provided by Mitsubishi Pharma Corporation (Yokohama, Japan). Retrorsine, Collagenase 
typeⅣ, bovine serum albumin, and purified rat albumin were purchased from Sigma Chemical 
Co. (St. Louis, MO). Purified rabbit anti-rat albumin IgG antibodies and peroxidase conjugated 
rabbit anti-rat albumin were obtained from ICN Pharmaceuticals Inc.(Aurora, OH). 
Hepatocyte Isolation and transplantation. Hepatocytes were isolated from SD rats according 
to a standard two-step collagenase perfusion technique (24). After enrichment through a Percoll 
gradient, hepatocytes viability was determined by the trypan blue exclusion test. The final 
viability of the purified hepatocytes suspension was always 90-95%. A suspension of 2×107 
viable hepatocytes in one milliliter of saline was directly infused via the portal vein. The NARs 
were given two injections of retrorsine, 30mg/kg each, intraperitoneally, 2 weeks apart. Four 
weeks after the second injection, each animal received 2×107 viable hepatocytes via the portal 
vein. After the HcTx, the continuous systemic administration (c.s.a.) of rhHGF or normal 
saline was done using an osmotic pump as described below. All animals were given Cyclosporin 
A, at a dose of 15mg/kg, intramuscularly one day prior to HcTx and every other day until 
sacrifice to limit rejection of the transplanted cells. 
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Continuous systemic administration of rhHGF. Alzet osmotic pumps were purchased from 
ALZA Co.(Palo Alto, CA). The pump was connected to the catheter canulated into the jugular 
vein and placed in the subcutaneous layer of the anterior wall. Continuous infusion of rhHGF or 
normal saline was done using an osmotic pump. 
Experimental designs. (Shown in Figure 1) The rats were divided into three experimental 
groups. The Group 1 (n=5) animals received retrorsine+HcTx  followed by c.s.a. of 
50μg/kg/day of rhHGF for 7 days. The Group 2 (n=5) animals received retrorsine+HcTx 
followed by c.s.a. of 250μg/kg/day of rhHGF for 7 days. The Group 3 (n=5) animals received 
retrorsine+HcTx followed by c.s.a. of normal saline for 7 days. HGF concentration was set 
according to our previous study (25). Blood samples were obtained from the tail vein on days 0 
(before HcTx), 3, 7, 14, 21, 28, 35, 42 and 56, respectively, for the determination of serum 
albumin. All animals were euthanized at the 56th day. At sacrifice, the liver specimens were 
fixed in 10% buffered formalin. 
Serum Albumin determination Quantitative analysis of the serum levels of albumin was 
carried out by sandwich ELISA using rabbit anti-rat albumin IgG described previously (26). 
Investigation of albumin positive hepatocytes Serial sections of the liver were immunostained 
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utilizing rabbit anti-rat albumin IgG antibody and an immunoperoxidase avidin-biotin 
peroxidase complex method. Albumin-positive area in the liver was quantitated with the help of 
a computer-assisted image analyzer. 
Measurement of serum human HGF concentration 
The human HGF concentration was measured by the Quantikine Human HGF EIA kit (R&D 
Systems, Inc., Minneapolis, MN) on day 3 to confirm the rise of the human HGF level for each 
administration of rhHGF. 
Measurement of serum rat endogenous HGF concentration 
The rat endogenous HGF concentration of rats given only retrorsine was measured by a rat HGF 
EIA kit (Institute of Immunology Co., Tokyo, Japan) on days 0 and 56 to check the host 
response against retrorsine (n=5). 
Statistical Analysis 
All data were expressed as a median and their range. Mann-Whitney’s test was used for the data 




                                                 
RESULTS 
Serum albumin level 
A significant increase in serum albumin levels were observed in each group following 
hepatocyte transplantation (v.s. base line levels; 1.26±0.04 ng/ml) (Figure 2). The serum 
albumin level of Group 1 was statistically higher than that of Group 2 at each point except for 
day 14 (p<0.05). There was no statistically significant difference in the serum albumin level 
between Groups 2 and 3. 
Albumin-positive hepatocytes in the liver 
The liver sections obtained from Group 1 showed a markedly large number of cells that stained 
positive for albumin. They were frequently observed as large clusters and occupied 
53.90±2.31% of host liver (Figure 3a). The liver sections obtained from Group 2 showed sparse 
albumin-positive hepatocytes. They were uniformly distributed throughout the liver parenchyma, 
and were not observed as clusters (Figure 3b). The liver sections obtained from Group 3 showed 
a large number of cells that stained positive for albumin. They were frequently observed as large 
clusters and occupied 31.25±5.36% of host liver, although there were fewer clusters than in 
Group 1(Figure 3c). There was statistically difference in the albumin-positive hepatocyte area 
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between group 1 and 3(p<0.05). 
Serum human HGF concentration 
The serum human HGF concentration through a c.s.a. of 50 and 250μg/kg/day of rhHGF were 
5.59±1.20 and 8.44±0.51 ng/ml, respectively (P<0.05). 
Serum endogenous rat HGF concentration 
The endogenous rat HGF concentration on days 0 and 56 were 25.01±0.19 and 20.14±1.29 
ng/ml, respectively, after retrorsine treatment. There was no statistically significant difference 
between the concentration on day 0 and that on day 56. 
 
DISCUSSION 
The present study demonstrated the enhanced effect of hepatocyte transplantation by the 
administration of low- dose rhHGF in rats treated with retrorsine as compared to that with 
high-dose rhHGF. 
We transplanted hepatocytes under the host’s hepatocyte proliferation potency control by 
retrorsine processing, and attempted selective proliferation of the transplanted hepatocytes. 
Pyrrolizidine alkaloids including retrorsine were studied originally because of their toxicity in 
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animals, particularly sheep and cattle, in which they cause both acute and chronic injury (19, 
20). The administration of a high dose of pyrrolizidine alkaloid is lethal, but a low dose induces 
only chronic hepatic megalocytosis (27). In our study, there were no death in the rats that only 
received retrorsine. Pyrrolizidine alkaloids are established hepatocarcinogens (28-32). However, 
Laconi E et al. (16) and Laconi S et al. (18, 33) maintained that animals treated with retrorsine 
for a long time without neoplastic change in the host’s hepatocytes and transplanted hepatocytes. 
To date, in order to inhibit the proliferation of endogenous hepatocytes, irradiation (34, 35) and 
anti-cancer drugs (36) have been used. Nevertheless, it is thought that those are not suitable in a 
clinical setting for co-effects to cells except hepatocytes. For the above reasons, we thought that 
retrorsine could likely be a drug which would the inhibit host’s hepatocyte proliferation potency 
in clinical application. 
In the present study, as a proliferation stimulus, instead of partial hepatectomy or portal 
branch ligation, rhHGF was administered, which was thought to be less invasive. In addition, 
carbon tetrachloride has been used as a proliferation stimulus for transplanted hepatocytes (37, 
38), but it is not thought to be suitable for use in a clinical setting. Strain et al. (11) reported that 
0.63ng/ml of rhHGF was the minimum concentration needed to stimulate hepatocyte 
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proliferation in a culture system. According to our previous study (25), when the rats were given 
a continuous systemic administration of rhHGF in a dose of 50μg/kg/day, the mean 
concentration of rhHGF in the portal blood was almost similar to the minimum concentration 
needed to stimulate hepatocyte proliferation in vitro. Based on this investigation, we considered 
that 50μg/kg/day should be given. We set the concentration of 250μg/kg/day as the high dose 
HGF, but could have set various concentrations of rhHGF between 50μg/kg/day and 
250μg/kg/day, or lower concentration than 50μg/kg/day. Furthermore, we planned to administer 
rhHGF by continuous systemic infusion because the half-life of HGF in plasma was very short 
in vivo and vitro (39-42). 
In the present study, the cell proliferation and function of the transplant hepatocytes of 
low-dose rhHGF were better than that with high-dose rhHGF. For that reason, since the rat 
endogenous HGF was already elevated by retrorsine treatment itself, high dose exogenous 
rhHGF administration was thought to counteract the proliferation of the transplanted 
hepatocytes. In fact, it was reported that there is a synergistic effect between rat HGF and 
rhHGF (40, 43). Furthermore, on the HGF concentration of 5-10ng/ml as growth stimuli, the 
DNA synthesis of the hepatocyte reaches a plateau, while the DNA synthesis is suppressed with 
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an HGF concentration of more than 10ng/ml (44). This is presumably the reason why the 
elevation of serum albumin was observed in Group 2 in the present study. In addition, 
cytoprotective effect rhHGF may be affecting the data. Whether infused rhHGF affect only 
transplanted hepatocytes, or only native hepatocytes injured by retrorsine, or both awaits further 
investigation. 
In conclusion, low-dose rather than high-dose rhHGF enhances the therapeutic effect of 
hepatocyte transplantation under retrorsine treatment. Since we only investigated 50μg/kg/day 
and 250μg/kg/day, further investigation is needed using a more optimal concentration of rhHGF. 
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FIGURE LEGENDS 
Figure 1 
NARs were given two injections of retrorsine, 30mg/kg each, intraperitoneally (i.p.), 2 weeks 
apart. Four weeks after the second injection, each animal received HcTx. After the HcTx, c.s.a. 
of rhHGF or normal saline was done. 
 
Figure 2 
A significant increase in the serum albumin level was observed in each group following 
hepatocyte transplantation. The serum albumin level of Group 1 was statistically higher than 
that of Group 2 at each point except for day 14 (p<0.05). There was no statistically significant 
difference between Groups 2 and 3. 
 
Figure 3 
(a) A large number of albumin-positive hepatocytes can be seen in Group 1, frequently as large 
clusters, which occupied 53.90±2.31% of host liver. 
(b) There are numerous albumin-positive hepatocytes in Group 2, which are distributed 
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throrough the liver parenchyma, but not seen as clusters. 
(c) A large number of albumin-positive hepatocytes can be seen in Group 3. They are frequently 
seen as large clusters, which occupied 31.25±5.36% of host liver. 
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Figure 3 
 
